Compare InnoCare Pharma Ltd. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.27%
- Poor long term growth as Operating profit has grown by an annual rate 50.50% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -46.59
2
Flat results in Dec 22
3
Risky -
4
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.15%
0%
-12.15%
6 Months
6.72%
0%
6.72%
1 Year
-24.29%
0%
-24.29%
2 Years
176.2%
0%
176.2%
3 Years
86.37%
0%
86.37%
4 Years
18.64%
0%
18.64%
5 Years
-54.57%
0%
-54.57%
InnoCare Pharma Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.35%
EBIT Growth (5y)
50.50%
EBIT to Interest (avg)
-34.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.86
Sales to Capital Employed (avg)
0.07
Tax Ratio
1.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.49%
ROE (avg)
0.27%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
2.13
EV to EBIT
19.56
EV to EBITDA
16.84
EV to Capital Employed
5.05
EV to Sales
4.23
PEG Ratio
0.06
Dividend Yield
NA
ROCE (Latest)
25.84%
ROE (Latest)
9.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
596.50
407.60
46.34%
Operating Profit (PBDIT) excl Other Income
76.40
3.60
2,022.22%
Interest
16.20
14.50
11.72%
Exceptional Items
3.80
2.70
40.74%
Consolidate Net Profit
115.60
15.50
645.81%
Operating Profit Margin (Excl OI)
128.10%
-68.50%
19.66%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 46.34% vs 125.94% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 645.81% vs 109.78% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,557.90
1,083.30
136.12%
Operating Profit (PBDIT) excl Other Income
618.90
-474.60
230.40%
Interest
59.70
37.10
60.92%
Exceptional Items
3.40
-33.00
110.30%
Consolidate Net Profit
698.60
-491.00
242.28%
Operating Profit Margin (Excl OI)
191.80%
-545.30%
73.71%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 136.12% vs 33.79% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 242.28% vs 31.17% in Dec 2024
About InnoCare Pharma Ltd. 
InnoCare Pharma Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






